Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia

Ann Hematol. 2016 Oct;95(11):1895-8. doi: 10.1007/s00277-016-2761-4. Epub 2016 Jul 29.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged, 80 and over
  • Antibodies, Bispecific / adverse effects
  • Antibodies, Bispecific / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow / pathology
  • Breast Neoplasms
  • Carcinoma, Transitional Cell
  • Cytarabine / administration & dosage
  • Female
  • Humans
  • Lymphoma, B-Cell
  • Mercaptopurine / administration & dosage
  • Methotrexate / administration & dosage
  • Neoplasms, Second Primary / drug therapy*
  • Neoplasms, Second Primary / pathology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Prednisone / administration & dosage
  • Remission Induction
  • Salvage Therapy*
  • Urinary Bladder Neoplasms
  • Vincristine / administration & dosage

Substances

  • Antibodies, Bispecific
  • Antineoplastic Agents
  • Cytarabine
  • blinatumomab
  • Vincristine
  • Mercaptopurine
  • Prednisone
  • Methotrexate

Supplementary concepts

  • POMP protocol